1
|
Kritchenkov IS, Solomatina AI, Kozina DO, Porsev VV, Sokolov VV, Shirmanova MV, Lukina MM, Komarova AD, Shcheslavskiy VI, Belyaeva TN, Litvinov IK, Salova AV, Kornilova ES, Kachkin DV, Tunik SP. Biocompatible Ir(III) Complexes as Oxygen Sensors for Phosphorescence Lifetime Imaging. Molecules 2021; 26:2898. [PMID: 34068190 PMCID: PMC8153025 DOI: 10.3390/molecules26102898] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 05/06/2021] [Accepted: 05/07/2021] [Indexed: 01/04/2023] Open
Abstract
Synthesis of biocompatible near infrared phosphorescent complexes and their application in bioimaging as triplet oxygen sensors in live systems are still challenging areas of organometallic chemistry. We have designed and synthetized four novel iridium [Ir(N^C)2(N^N)]+ complexes (N^C-benzothienyl-phenanthridine based cyclometalated ligand; N^N-pyridin-phenanthroimidazol diimine chelate), decorated with oligo(ethylene glycol) groups to impart these emitters' solubility in aqueous media, biocompatibility, and to shield them from interaction with bio-environment. These substances were fully characterized using NMR spectroscopy and ESI mass-spectrometry. The complexes exhibited excitation close to the biological "window of transparency", NIR emission at 730 nm, and quantum yields up to 12% in water. The compounds with higher degree of the chromophore shielding possess low toxicity, bleaching stability, absence of sensitivity to variations of pH, serum, and complex concentrations. The properties of these probes as oxygen sensors for biological systems have been studied by using phosphorescence lifetime imaging experiments in different cell cultures. The results showed essential lifetime response onto variations in oxygen concentration (2.0-2.3 μs under normoxia and 2.8-3.0 μs under hypoxia conditions) in complete agreement with the calibration curves obtained "in cuvette". The data obtained indicate that these emitters can be used as semi-quantitative oxygen sensors in biological systems.
Collapse
Affiliation(s)
- Ilya S. Kritchenkov
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| | - Anastasia I. Solomatina
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| | - Daria O. Kozina
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| | - Vitaly V. Porsev
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| | - Victor V. Sokolov
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| | - Marina V. Shirmanova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhskiy Research Medical University, Minin and Pozharsky sq. 10/1, 603005 Nizhny Novgorod, Russia; (M.V.S.); (M.M.L.); (A.D.K.); (V.I.S.)
| | - Maria M. Lukina
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhskiy Research Medical University, Minin and Pozharsky sq. 10/1, 603005 Nizhny Novgorod, Russia; (M.V.S.); (M.M.L.); (A.D.K.); (V.I.S.)
| | - Anastasia D. Komarova
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhskiy Research Medical University, Minin and Pozharsky sq. 10/1, 603005 Nizhny Novgorod, Russia; (M.V.S.); (M.M.L.); (A.D.K.); (V.I.S.)
| | - Vladislav I. Shcheslavskiy
- Institute of Experimental Oncology and Biomedical Technologies, Privolzhskiy Research Medical University, Minin and Pozharsky sq. 10/1, 603005 Nizhny Novgorod, Russia; (M.V.S.); (M.M.L.); (A.D.K.); (V.I.S.)
- Becker&Hickl GmbH, Nunsdorfer Ring 7-9, 12277 Berlin, Germany
| | - Tatiana N. Belyaeva
- Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky av. 4, 194064 St. Petersburg, Russia; (T.N.B.); (I.K.L.); (A.V.S.); (E.S.K.)
| | - Ilia K. Litvinov
- Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky av. 4, 194064 St. Petersburg, Russia; (T.N.B.); (I.K.L.); (A.V.S.); (E.S.K.)
| | - Anna V. Salova
- Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky av. 4, 194064 St. Petersburg, Russia; (T.N.B.); (I.K.L.); (A.V.S.); (E.S.K.)
| | - Elena S. Kornilova
- Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky av. 4, 194064 St. Petersburg, Russia; (T.N.B.); (I.K.L.); (A.V.S.); (E.S.K.)
- Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnical University, Khlopina Str. 11, 194021 St. Petersburg, Russia
| | - Daniel V. Kachkin
- Faculty of Biology, St. Petersburg State University, Universitetskaya emb., 7/9, 199034 St. Petersburg, Russia;
| | - Sergey P. Tunik
- Institute of Chemistry, St. Petersburg State University, Universitetskii av., 26, 198504 St. Petersburg, Russia; (I.S.K.); (A.I.S.); (D.O.K.); (V.V.P.); (V.V.S.)
| |
Collapse
|
2
|
Li H, Luo Q, Zhu H, Li Z, Wang X, Roberts N, Zhang H, Gong Q, Gu Z, Luo K. An advanced micelle-based biodegradable HPMA polymer-gadolinium contrast agent for MR imaging of murine vasculatures and tumors. Polym Chem 2020. [DOI: 10.1039/d0py01133a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A biodegradable HPMA polymeric micelle-based MR contrast agent containing gadolinium (Gd3+) for imaging murine vascular structures and tumors.
Collapse
|
3
|
Vangijzegem T, Stanicki D, Boutry S, Paternoster Q, Vander Elst L, Muller RN, Laurent S. VSION as high field MRI T 1 contrast agent: evidence of their potential as positive contrast agent for magnetic resonance angiography. NANOTECHNOLOGY 2018; 29:265103. [PMID: 29620535 DOI: 10.1088/1361-6528/aabbd0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Because of their outstanding magnetic properties, iron oxide nanoparticles have already been the subject of numerous studies in the biomedical field, in particular as a negative contrast agent for T2-weighted nuclear magnetic resonance imaging, or as therapeutic agents in hyperthermia experiments. Recent studies have shown that below a given particle size (i.e. 5 nm), iron oxide may be used to provide a significant positive (brightening) effect on T1-weighted MRI. In such an application, not only the size of the crystal, but also the control of the coating process is essential to ensure optimal properties, especially at a very high field (> 3 T). In this work, we focused on the development of very small iron oxide nanoparticles as a potential platform for high field T1 magnetic resonance angiography (MRA) applications. The feasibility has been evaluated in vivo at 9.4 T, demonstrating the usefulness of the developed system for MRA applications.
Collapse
Affiliation(s)
- T Vangijzegem
- Department of General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons, B-7000 Mons, Belgium
| | | | | | | | | | | | | |
Collapse
|
4
|
Chytil P, Koziolová E, Etrych T, Ulbrich K. HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release. Macromol Biosci 2017; 18. [PMID: 28805040 DOI: 10.1002/mabi.201700209] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Indexed: 11/10/2022]
Abstract
Over the past few decades, numerous polymer drug carrier systems are designed and synthesized, and their properties are evaluated. Many of these systems are based on water-soluble polymer carriers of low-molecular-weight drugs and compounds, e.g., cytostatic agents, anti-inflammatory drugs, or multidrug resistance inhibitors, all covalently bound to a carrier by a biodegradable spacer that enables controlled release of the active molecule to achieve the desired pharmacological effect. Among others, the synthetic polymer carriers based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers are some of the most promising carriers for this purpose. This review focuses on advances in the development of HPMA copolymer carriers and their conjugates with anticancer drugs, with triggered drug activation in tumor tissue and especially in tumor cells. Specifically, this review highlights the improvements in polymer drug carrier design with respect to the structure of a spacer to influence controlled drug release and activation, and its impact on the drug pharmacokinetics, enhanced tumor uptake, cellular trafficking, and in vivo antitumor activity.
Collapse
Affiliation(s)
- Petr Chytil
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
| | - Eva Koziolová
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
| | - Tomáš Etrych
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
| | - Karel Ulbrich
- Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic
| |
Collapse
|
5
|
Cyclen-based double-tailed lipids for DNA delivery: Synthesis and the effect of linking group structures. Bioorg Med Chem 2015. [DOI: 10.1016/j.bmc.2015.07.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
6
|
Abstract
Nanoparticles are frequently suggested as diagnostic agents. However, except for iron oxide nanoparticles, diagnostic nanoparticles have been barely incorporated into clinical use so far. This is predominantly due to difficulties in achieving acceptable pharmacokinetic properties and reproducible particle uniformity as well as to concerns about toxicity, biodegradation, and elimination. Reasonable indications for the clinical utilization of nanoparticles should consider their biologic behavior. For example, many nanoparticles are taken up by macrophages and accumulate in macrophage-rich tissues. Thus, they can be used to provide contrast in liver, spleen, lymph nodes, and inflammatory lesions (eg, atherosclerotic plaques). Furthermore, cells can be efficiently labeled with nanoparticles, enabling the localization of implanted (stem) cells and tissue-engineered grafts as well as in vivo migration studies of cells. The potential of using nanoparticles for molecular imaging is compromised because their pharmacokinetic properties are difficult to control. Ideal targets for nanoparticles are localized on the endothelial luminal surface, whereas targeted nanoparticle delivery to extravascular structures is often limited and difficult to separate from an underlying enhanced permeability and retention (EPR) effect. The majority of clinically used nanoparticle-based drug delivery systems are based on the EPR effect, and, for their more personalized use, imaging markers can be incorporated to monitor biodistribution, target site accumulation, drug release, and treatment efficacy. In conclusion, although nanoparticles are not always the right choice for molecular imaging (because smaller or larger molecules might provide more specific information), there are other diagnostic and theranostic applications for which nanoparticles hold substantial clinical potential.
Collapse
Affiliation(s)
- Fabian Kiessling
- From the Department of Experimental Molecular Imaging, RWTH-Aachen University, Aachen, Germany (F.K., M.E.M., T.L.); and Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY (J.G.)
| | | | | | | |
Collapse
|
7
|
Theek B, Gremse F, Kunjachan S, Fokong S, Pola R, Pechar M, Deckers R, Storm G, Ehling J, Kiessling F, Lammers T. Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. J Control Release 2014; 182:83-9. [PMID: 24631862 DOI: 10.1016/j.jconrel.2014.03.007] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 02/28/2014] [Accepted: 03/03/2014] [Indexed: 12/31/2022]
Abstract
The Enhanced Permeability and Retention (EPR) effect is extensively used in drug delivery research. Taking into account that EPR is a highly variable phenomenon, we have here set out to evaluate if contrast-enhanced functional ultrasound (ceUS) imaging can be employed to characterize EPR-mediated passive drug targeting to tumors. Using standard fluorescence molecular tomography (FMT) and two different protocols for hybrid computed tomography-fluorescence molecular tomography (CT-FMT), the tumor accumulation of a ~10 nm-sized near-infrared-fluorophore-labeled polymeric drug carrier (pHPMA-Dy750) was evaluated in CT26 tumor-bearing mice. In the same set of animals, two different ceUS techniques (2D MIOT and 3D B-mode imaging) were employed to assess tumor vascularization. Subsequently, the degree of tumor vascularization was correlated with the degree of EPR-mediated drug targeting. Depending on the optical imaging protocol used, the tumor accumulation of the polymeric drug carrier ranged from 5 to 12% of the injected dose. The degree of tumor vascularization, determined using ceUS, varied from 4 to 11%. For both hybrid CT-FMT protocols, a good correlation between the degree of tumor vascularization and the degree of tumor accumulation was observed, within the case of reconstructed CT-FMT, correlation coefficients of ~0.8 and p-values of <0.02. These findings indicate that ceUS can be used to characterize and predict EPR, and potentially also to pre-select patients likely to respond to passively tumor-targeted nanomedicine treatments.
Collapse
Affiliation(s)
- Benjamin Theek
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Felix Gremse
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Sijumon Kunjachan
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Stanley Fokong
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Robert Pola
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Michal Pechar
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Roel Deckers
- Imaging Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Department of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Josef Ehling
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Fabian Kiessling
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany
| | - Twan Lammers
- Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH-Aachen University, Aachen, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Department of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
| |
Collapse
|
8
|
Wang Z, Niu G, Chen X. Polymeric materials for theranostic applications. Pharm Res 2013; 31:1358-76. [PMID: 23765400 DOI: 10.1007/s11095-013-1103-7] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2012] [Accepted: 06/04/2013] [Indexed: 12/29/2022]
Abstract
Nanotechnology has continuously contributed to the fast development of diagnostic and therapeutic agents. Theranostic nanomedicine has encompassed the ongoing efforts on concurrent molecular imaging of biomarkers, delivery of therapeutic agents, and monitoring of therapy response. Among these formulations, polymer-based theranostic agents hold great promise for the construction of multifunctional agents for translational medicine. In this article, we reviewed the state-of-the-art polymeric nanoparticles, from preparation to application, as potential theranostic agents for diagnosis and therapy. We summarized several major polymer formulas, including polymeric conjugate complexes, nanospheres, micelles, and dendrimers for integrated molecular imaging and therapeutic applications.
Collapse
Affiliation(s)
- Zhe Wang
- Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering National Institutes of Health, Bldg. 31, 1C22, Bethesda, Maryland, 20892, USA
| | | | | |
Collapse
|
9
|
Soleimani A, Martínez F, Economopoulos V, Foster PJ, Scholl TJ, Gillies ER. Polymer cross-linking: a nanogel approach to enhancing the relaxivity of MRI contrast agents. J Mater Chem B 2013; 1:1027-1034. [DOI: 10.1039/c2tb00352j] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
10
|
Bryson J, Reineke JW, Reineke TM. Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential? Macromolecules 2012; 45:8939-8952. [PMID: 23467737 DOI: 10.1021/ma301568u] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Macromolecular magnetic resonance imaging (MRI) contrast agents are increasingly being used to improve the resolution of this noninvasive diagnostic technique. All clinically-approved T1 contrast agents are small molecule chelates of gadolinium [Gd(III)] that affect bound water proton relaxivity. Both the small size and monomeric nature of these agents ultimately limits the image resolution enhancement that can be achieved for both contrast enhancement and pharmacokinetic/biodistribution reasons. The multimeric nature of macromolecules, such as polymers, dendrimers, and noncovalent complexes of small molecule agents with proteins, have been shown to significantly increase the image contrast and resolution due to their large size and ability to incorporate multiple Gd(III) chlelation sites. Also, macromolecular agents are advantageous as they have the ability to be designed to be nontoxic, hydrophilic, easily purified, aggregation-resistant, and have controllable three-dimensional macromolecular structure housing the multiple lanthanide chelation sites. For these reasons, large molecule diagnostics have the ability to significantly increase the relaxivity of water protons within the targeted tissues and thus the image resolution for many diagnostic applications. The FDA approval of a contrast agent that consists of a reversible, non-covalent coupling of a small Gd(III) chelate with serum albumin for blood pool imaging (marketed under the trade names of Vasovist and Ablivar) proved to be one of the first diagnostic agent to capitalize on these benefits from macromolecular association in humans. However, much research and development is necessary to optimize the safety of these unique agents for in vivo use and potential clinical development. To this end, recent work in the field of polymer, dendrimer, and noncovalent complex-based imaging agents are reviewed herein and the future outlook of this field is discussed.
Collapse
|
11
|
Abstract
Nanomedicine formulations aim to improve the biodistribution and the target site accumulation of systemically administered (chemo)therapeutic agents. Many different types of nanomedicines have been evaluated over the years, including for instance liposomes, polymers, micelles and antibodies, and a significant amount of evidence has been obtained showing that these submicrometer-sized carrier materials are able to improve the balance between the efficacy and the toxicity of therapeutic interventions. Besides for therapeutic purposes, nanomedicine formulations have in recent years also been increasingly employed for imaging applications. Moreover, paralleled by advances in chemistry, biology, pharmacy, nanotechnology, medicine and imaging, several different systems have been developed in the last decade in which disease diagnosis and therapy are combined. These so-called (nano) theranostics contain both a drug and an imaging agent within a single formulation, and they can be used for various different purposes. In this Account, we summarize several exemplary efforts in this regard, and we show that theranostic nanomedicines are highly suitable systems for monitoring drug delivery, drug release and drug efficacy. The (pre)clinically most relevant applications of theranostic nanomedicines relate to their use for validating and optimizing the properties of drug delivery systems, and to their ability to be used for pre-screening patients and enabling personalized medicine. Regarding the former, the combination of diagnostic and therapeutic agents within a single formulation provides real-time feedback on the pharmacokinetics, the target site localization and the (off-target) healthy organ accumulation of nanomedicines. Various examples of this will be highlighted in this Account, illustrating that by non-invasively visualizing how well carrier materials are able to deliver pharmacologically active agents to the pathological site, and how well they are able to prevent them from accumulating in potentially endangered healthy tissues, important information can be obtained for optimizing the basic properties of drug delivery systems, as well as for improving the balance between the efficacy and the toxicity of targeted therapeutic interventions. Regarding personalized medicine, it can be reasoned that only in patients which show high levels of target site accumulation, and which respond well to the first couple of treatment cycles, targeted therapy should be continued, and that in those in which this is not the case, other therapeutic options should be considered. Based on these insights, we expect that ever more efforts will be invested in developing theranostic nanomedicines, and that these systems and strategies will contribute substantially to realizing the potential of personalized medicine.
Collapse
Affiliation(s)
- Twan Lammers
- Department of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH - Aachen University, Pauwelsstrasse 20, 52074 Aachen, Germany
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
- Department of Innovative Cancer Diagnosis and Therapy, Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Silvio Aime
- Department of Chemistry IFM and Molecular Imaging Center, University of Torino, Via P. Giuria 7, 10125 Torino, Italy
| | - Wim E. Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
| | - Fabian Kiessling
- Department of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH - Aachen University, Pauwelsstrasse 20, 52074 Aachen, Germany
| |
Collapse
|
12
|
Huis In 't Veld R, Storm G, Hennink WE, Kiessling F, Lammers T. Macromolecular nanotheranostics for multimodal anticancer therapy. NANOSCALE 2011; 3:4022-4034. [PMID: 21901211 DOI: 10.1039/c1nr10733j] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Macromolecular carrier materials based on N-(2-hydroxypropyl)methacrylamide (HPMA) are prototypic and well-characterized drug delivery systems that have been extensively evaluated in the past two decades, both at the preclinical and at the clinical level. Using several different imaging agents and techniques, HPMA copolymers have been shown to circulate for prolonged periods of time, and to accumulate in tumors both effectively and selectively by means of the Enhanced Permeability and Retention (EPR) effect. Because of this, HPMA-based macromolecular nanotheranostics, i.e. formulations containing both drug and imaging agents within a single formulation, have been shown to be highly effective in inducing tumor growth inhibition in animal models. In patients, however, as essentially all other tumor-targeted nanomedicines, they are generally only able to improve the therapeutic index of the attached active agent by lowering its toxicity, and they fail to improve the efficacy of the intervention. Bearing this in mind, we have recently reasoned that because of their biocompatibility and their beneficial biodistribution, nanomedicine formulations might be highly suitable systems for combination therapies. In the present manuscript, we briefly summarize several exemplary efforts undertaken in this regard in our labs in the past couple of years, and we show that long-circulating and passively tumor-targeted macromolecular nanotheranostics can be used to improve the efficacy of radiochemotherapy and of chemotherapy combinations.
Collapse
Affiliation(s)
- Ruben Huis In 't Veld
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
13
|
Frullano L, Caravan P. Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth 2011; 8:535-565. [PMID: 22375102 DOI: 10.2174/157017911796117250] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The development of gadolinium chelators that can be easily and readily linked to various substrates is of primary importance for the development high relaxation efficiency and/or targeted magnetic resonance imaging (MRI) contrast agents. Over the last 25 years a large number of bifunctional chelators have been prepared. For the most part, these compounds are based on ligands that are already used in clinically approved contrast agents. More recently, new bifunctional chelators have been reported based on complexes that show a more potent relaxation effect, faster complexation kinetics and in some cases simpler synthetic procedures. This review provides an overview of the synthetic strategies used for the preparation of bifunctional chelators for MRI applications.
Collapse
Affiliation(s)
- Luca Frullano
- Case Western Reserve University. 11100 Euclid Ave Cleveland, OH 44106
| | | |
Collapse
|
14
|
Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G, Kiessling F. HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine (Lond) 2011; 5:1501-23. [PMID: 21143030 DOI: 10.2217/nnm.10.130] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
To assist intravenously administered anticancer agents in achieving proper circulation times and tumor concentrations, and to thereby improve the balance between their efficacy and their toxicity, a large number of drug delivery systems have been designed and evaluated over the years. Clinically relevant examples of such nanometer-sized carrier materials are liposomes, polymers, micelles and antibodies. In the vast majority of cases, however, and especially in patients, nanomedicine formulations are only able to attenuate the toxicity of the conjugated or entrapped chemotherapeutic drug, and they generally fail to improve the efficacy of the intervention. To overcome this shortcoming, and to broaden the clinical applicability of tumor-targeted nanomedicines, in the past 5 years we have developed several concepts for using N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer therapeutics to enhance the efficacy of combined modality anticancer therapy. Regarding surgery, HPMA copolymers were shown to be able to improve the retention of intratumorally administered chemotherapeutic agents at the pathological site, and to thereby increase their therapeutic index. Regarding radiotherapy, a synergistic interaction was observed, with radiotherapy improving the tumor accumulation of the copolymers, and with copolymers improving both the efficacy and the tolerability of radiochemotherapy. Futhermore, regarding chemotherapy combinations, we have for the first time provided in vivo evidence showing that passively tumor-targeted polymeric drug carriers can be used to deliver two different drugs to tumors simultaneously. Based on these findings, and on the fact that the concepts developed are considered to be broadly applicable, we conclude that nanomedicine formulations are highly suitable systems for improving the efficacy of combined modality anticancer therapy.
Collapse
Affiliation(s)
- Twan Lammers
- Department of Experimental Molecular Imaging, RWTH-Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Song Y, Zong H, Trivedi ER, Vesper BJ, Waters EA, Barrett AGM, Radosevich JA, Hoffman BM, Meade TJ. Synthesis and characterization of new porphyrazine-Gd(III) conjugates as multimodal MR contrast agents. Bioconjug Chem 2010; 21:2267-75. [PMID: 21062033 DOI: 10.1021/bc1002828] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Magnetic resonance imaging (MRI) has long been used clinically and experimentally as a diagnostic tool to obtain three-dimensional, high-resolution images of deep tissues. These images are enhanced by the administration of contrast agents such as paramagnetic Gd(III) complexes. Herein, we describe the preparation of a series of multimodal imaging agents in which paramagnetic Gd(III) complexes are conjugated to a fluorescent tetrapyrrole, namely, a porphyrazine (pz). Zinc metalated pzs conjugated to one, four, or eight paramagnetic Gd(III) complexes are reported. Among these conjugates, Zn-Pz-8Gd(III) exhibits an ionic relaxivity four times that of the monomeric Gd(III) agent, presumably because of increased molecular weight and a molecular relaxivity that is approximately thirty times larger, while retaining the intense electronic absorption and emission of the unmodified pz. Unlike current clinical MR agents, Zn-Pz-1Gd(III) is taken up by cells. This probe demonstrates intracellular fluorescence by confocal microscopy and provides significant contrast enhancement in MR images, as well as marked phototoxicity in assays of cellular viability. These results suggest that pz agents possess a new potential for use in cancer imaging by both MRI and near-infrared (NIR) fluorescence, while acting as a platform for photodynamic therapy.
Collapse
Affiliation(s)
- Ying Song
- Department of Chemistry, Northwestern University, Evanston, Illinois, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010; 7:1899-912. [PMID: 20822168 DOI: 10.1021/mp100228v] [Citation(s) in RCA: 310] [Impact Index Per Article: 22.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Nanomedicine formulations aim to improve the biodistribution and the target site accumulation of systemically applied (chemo-) therapeutics. Various different passively and actively targeted nanomedicines have been evaluated over the years, based e.g. on liposomes, polymers, micelles and antibodies, and a significant amount of (pre-) clinical evidence has been obtained showing that these 5-200 nm sized carrier materials are able to improve the therapeutic index of low-molecular-weight drugs. Besides for therapeutic purposes, however, nanomedicine formulations have also been more and more used for imaging applications, as well as, in recent years, for theranostic approaches, i.e. for systems and strategies in which disease diagnosis and therapy are combined. Potential applications of theranostic nanomedicine formulations range from the noninvasive assessment of the biodistribution and the target site accumulation of low-molecular-weight drugs, and the visualization of drug distribution and drug release at the target site, to the optimization of strategies relying on triggered drug release, and the prediction and real-time monitoring of therapeutic responses. Nanotheranostic systems are consequently considered to be highly suitable systems for (pre-) clinical implementation, not only because they might assist in better understanding various important aspects of the drug delivery process, and in developing better drug delivery systems, but also because they might contribute to realizing the potential of "personalized medicine", and to developing more effective and less toxic treatment regimens for individual patients.
Collapse
Affiliation(s)
- Twan Lammers
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
17
|
Lee JH, Sherlock SP, Terashima M, Kosuge H, Suzuki Y, Goodwin A, Robinson J, Seo WS, Liu Z, Luong R, McConnell MV, Nishimura DG, Dai H. High-contrast in vivo visualization of microvessels using novel FeCo/GC magnetic nanocrystals. Magn Reson Med 2010; 62:1497-509. [PMID: 19859938 DOI: 10.1002/mrm.22132] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
FeCo-graphitic carbon shell nanocrystals are a novel MRI contrast agent with unprecedented high per-metal-atom-basis relaxivity (r(1) = 97 mM(-1) sec(-1), r(2) = 400 mM(-1) sec(-1)) and multifunctional capabilities. While the conventional gadolinium-based contrast-enhanced angiographic magnetic MRI has proven useful for diagnosis of vascular diseases, its short circulation time and relatively low sensitivity render high-resolution MRI of morphologically small vascular structures such as those involved in collateral, arteriogenic, and angiogenic vessel formation challenging. Here, by combining FeCo-graphitic carbon shell nanocrystals with high-resolution MRI technique, we demonstrate that such microvessels down to approximately 100 mum can be monitored in high contrast and noninvasively using a conventional 1.5-T clinical MRI system, achieving a diagnostic imaging standard approximating that of the more invasive X-ray angiography. Preliminary in vitro and in vivo toxicity study results also show no sign of toxicity.
Collapse
Affiliation(s)
- Jin Hyung Lee
- Department of Electrical Engineering, Stanford University, Stanford, California 94305-5080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 2009; 99:900-10. [PMID: 19238631 PMCID: PMC2538765 DOI: 10.1038/sj.bjc.6604561] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Drug targeting systems are nanometer-sized carrier materials designed for improving the biodistribution of systemically applied (chemo-) therapeutics. Reasoning that (I) the temporal and spatial interaction between systemically applied chemotherapy and clinically relevant fractionated radiotherapy is suboptimal, and that (II) drug targeting systems are able to improve the temporal and spatial parameters of this interaction, we have here set out to evaluate the potential of 'carrier-based radiochemotherapy'. N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were used as a model drug targeting system, doxorubicin and gemcitabine as model drugs, and the syngeneic and radio- and chemoresistant Dunning AT1 rat prostate carcinoma as a model tumour model. Using magnetic resonance imaging and gamma-scintigraphy, the polymeric drug carriers were first shown to circulate for prolonged periods of time, to localise to tumours both effectively and selectively, and to improve the tumour-directed delivery of low molecular weight agents. Subsequently, they were then shown to interact synergistically with radiotherapy, with radiotherapy increasing the tumour accumulation of the copolymers, and with the copolymers increasing the therapeutic index of radiochemotherapy (both for doxorubicin and for gemcitabine). Based on these findings, and on the fact that its principles are likely broadly applicable, we propose carrier-based radiochemotherapy as a novel concept for treating advanced solid malignancies.
Collapse
|
19
|
Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm Res 2009; 26:1121-9. [PMID: 19160028 DOI: 10.1007/s11095-009-9830-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2008] [Accepted: 01/12/2009] [Indexed: 01/27/2023]
Abstract
PURPOSE To evaluate the tumor targeting potential of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-gadolinium(Gd)-RGDfK conjugates by magnetic resonance (MR) T1-mapping. METHODS HPMA copolymers with and without RGDfK were synthesized to incorporate side chains for Gd chelation. The conjugates were characterized by their side-chain contents and r(1) relaxivity. In vitro integrin-binding affinities of polymeric conjugates were assessed via competitive cell binding assays on HUVEC endothelial cells and MDA-MB-231 breast cancer cells. In vivo MR imaging was performed on MDA-MB-231 tumor-bearing SCID mice at different time points using non-targetable and targetable polymers. The specificity of alphavbeta3 targeting was assessed by using non-paramagnetic targetable polymer to block alphavbeta3 integrins followed by injection of paramagnetic targetable polymers after 2 h. RESULTS The polymer conjugates showed relaxivities higher than Gd-DOTA. Endothelial cell binding studies showed that IC(50) values for the copolymer with RGDfK binding to alphavbeta3 integrin-positive HUVEC and MDA-MB-231 cells were similar to that of free peptide. Significantly lower T1 values were observed at the tumor site after 2 h using targetable conjugate (p < 0.012). In vivo blocking study showed significantly higher T1 values (p < 0.045) compared to targetable conjugate. CONCLUSION These results demonstrate the potential of this conjugate as an effective targetable MR contrast agent for tumor imaging and therapy monitoring.
Collapse
|
20
|
Lammers T, Subr V, Ulbrich K, Peschke P, Kiessling F, Huber P, Hennink W, Storm G. Carrier-based radiochemotherapy. J Control Release 2008. [DOI: 10.1016/j.jconrel.2008.09.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Zarabi B, Nan A, Zhuo J, Gullapalli R, Ghandehari H. HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation. Macromol Biosci 2008; 8:741-8. [PMID: 18484565 PMCID: PMC2704051 DOI: 10.1002/mabi.200700290] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This study describes the synthesis, characterization, and in vitro evaluation of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-gadolinium (Gd)-doxorubicin (Dox) conjugates. Copolymers of HPMA were derivatized to incorporate side chains for Gd chelation and Dox conjugation. The conjugates were characterized by their side chain contents, T(1) relaxivity (r(1)), stability, and in vitro cytotoxicity. High stability and relaxivity of these conjugates coupled with low toxicity show their potential for monitoring the in vivo fate of HPMA-based drug delivery systems by magnetic resonance imaging techniques.
Collapse
Affiliation(s)
- Bahar Zarabi
- Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, USA
| | | | | | | | | |
Collapse
|
22
|
Berret JF, Sandre O, Mauger A. Size distribution of superparamagnetic particles determined by magnetic sedimentation. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2007; 23:2993-9. [PMID: 17284055 DOI: 10.1021/la061958w] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
We report on the use of magnetic sedimentation as a means to determine the size distribution of dispersed magnetic particles. The particles investigated here are (i) single anionic and cationic nanoparticles of diameter D approximately 7 nm and (ii) nanoparticle clusters resulting from electrostatic complexation with polyelectrolytes and polyelectrolyte-neutral copolymers. A theoretical expression of the sedimentation concentration profiles at the steady state is proposed, and it is found to accurately describe the experimental data. When compared to dynamic light scattering, vibrating sample magnetometry, and cryogenic transmission electron microscopy, magnetic sedimentation exhibits a unique property: it provides the core size and core size distribution of nanoparticle aggregates.
Collapse
Affiliation(s)
- J-F Berret
- Matière et Systèmes Complexes, UMR 7057 CNRS Université Denis Diderot Paris-VII, 140 rue de Lourmel, F-75015 Paris, France.
| | | | | |
Collapse
|
23
|
Kiessling F, Jugold M, Woenne EC, Brix G. Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur Radiol 2007; 17:2136-48. [PMID: 17308924 DOI: 10.1007/s00330-006-0566-x] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Revised: 11/13/2006] [Accepted: 12/19/2006] [Indexed: 02/07/2023]
Abstract
The switch to an angiogenic phenotype is an important precondition for tumor growth, invasion and spread. Since newly formed vessels are characterized by structural, functional and molecular abnormalities, they offer promising targets for tumor diagnosis and therapy. Previous studies indicate that MRI is valuable to assess vessel morphology and function. It can be used to distinguish between benign and malignant lesions and to improve delineation of proliferating areas within heterogeneous tumors. In addition, tracer kinetic analysis of contrast-enhanced image series allows the estimation of well-defined physiological parameters such as blood volume, blood flow and vessel permeability. Frequently, changes of these parameters during cytostatic, anti-angiogenic and radiation therapy precede tumor volume reduction. Moreover, target-specific MRI techniques can be used to elucidate the expression of angiogenic markers at the molecular level. This review summarizes strategies for non-invasive characterization of tumor vascularization by functional and molecular MRI, hereby introducing representative preclinical and clinical applications.
Collapse
Affiliation(s)
- Fabian Kiessling
- Junior Group Molecular Imaging, German Cancer Research Center, INF 280, 96121,Heidelberg, Germany.
| | | | | | | |
Collapse
|
24
|
Zarabi B, Nan A, Zhuo J, Gullapalli R, Ghandehari H. Macrophage targeted N-(2-hydroxypropyl)methacrylamide conjugates for magnetic resonance imaging. Mol Pharm 2007; 3:550-7. [PMID: 17009854 DOI: 10.1021/mp060072i] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
This study describes the synthesis, characterization and in vitro evaluation of targetable N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-gadolinium (Gd) chelates for enhanced magnetic resonance imaging (MRI) of macrophages. Copolymers of HPMA, methacryloylglycylglycyl-mannosamine (MA-GG-ManN), aminopropylmethacrylamide-benzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (APMA-DOTA), and 5-(3-(methacryloylaminopropyl)thioureidyl) fluorescein (MA-AP-FITC) were synthesized and characterized. Gd was chelated to the polymeric precursors. The conjugates were characterized for gadolinium content by inductively coupled plasma optical emission spectrometry (ICP-OES) and T1 relaxivity (r1) at room temperature and 1.5 T. The effect of ManN content on mannose receptor mediated uptake of THP-1 human macrophages was evaluated as a function of time and temperature. The polymer conjugates showed relaxivities in the range of 21.8-24.9 s(-1) mM(-1) Gd. Relaxivities of the conjugates per mM Gd were up to 7 times higher than that of a commercially available MR contrast agent Gd-DOTA. Significantly (p < 0.042) higher uptake was observed for targeted conjugates compared to nontargeted conjugates. The uptake of polymeric conjugates was time and concentration dependent and appears to be mannose receptor mediated. The increased relaxivity coupled with the ability to target these carriers to cells containing ManN receptors shows promise for the application of these agents in clinical MR imaging of macrophage mediated malignancies.
Collapse
Affiliation(s)
- Bahar Zarabi
- Department of Pharmaceutical Sciences, Center for Nanomedicine and Cellular Delivery, University of Maryland, Baltimore, Maryland 21201, USA.
| | | | | | | | | |
Collapse
|
25
|
Giesel FL, Stroick M, Griebe M, Tröster H, von der Lieth CW, Requardt M, Rius M, Essig M, Kauczor HU, Hennerici MG, Fatar M. Gadofluorine M Uptake in Stem Cells as a New Magnetic Resonance Imaging Tracking Method. Invest Radiol 2006; 41:868-73. [PMID: 17099425 DOI: 10.1097/01.rli.0000246147.44835.4c] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
OBJECTIVES Cell tracking using ultrasmall iron particles is well established in magnetic resonance imaging (MRI). However, in experimental models, intrinsic iron signals derived from erythrocytes mask the labeled cells. Therefore, we evaluated Gadofluorine M with other gadolinium chelates for a T1-weighted positive enhancement for cell tracking in vitro. In addition, Gadofluorine M was tested in vivo. MATERIAL AND METHODS Gadofluorine M and other gadolinium chelates were used to label stem cells with and without uptake-mediating agents in vitro and in vivo using a 1.5 T MRI. In addition, histology and molecular modeling was investigated. RESULTS Gadofluorine M revealed comparable properties to an uptake mediating agent in molecular modeling. Without an uptake-mediating agent Gadofluorine M-labeled cells were detected as a T1-weighted positive contrast in vitro and in vivo. Histology confirmed a 100% success rate for intracellular labeling. CONCLUSION This study describes a novel contrast agent with the capability of intracellular accumulation without an uptake mediator providing a T1-positive MRI signal at 1.5 T and may be suitable for cell tracking in animal models with intraparenchymal hemorrhages such as stroke or malignant tumors.
Collapse
|